Everolimus-eluting versus sirolimus-eluting stents in patients undergoing percutaneous coronary intervention: The excellent (efficacy of Xience/Promus versus cypher to reduce late loss after stenting) randomized trial

Kyung Woo Park, In Ho Chae, Do Sun Lim, Kyoo Rok Han, Han Mo Yang, Hae Young Lee, Hyun Jae Kang, Bon Kwon Koo, Taehoon Ahn, Jung Han Yoon, Myung Ho Jeong, Taek Jong Hong, Woo Young Chung, Sang Ho Jo, Young Jin Choi, Seung Ho Hur, Hyuck Moon Kwon, Dong Woon Jeon, Byung Ok Kim, Si Hoon ParkNam Ho Lee, Hui Kyung Jeon, Hyeon Cheol Gwon, Yang Soo Jang, Hyo Soo Kim

Research output: Contribution to journalArticlepeer-review

124 Citations (Scopus)


Objectives: The goal of this study was to compare the angiographic outcomes of everolimus-eluting stents (EES) and sirolimus-eluting stents (SES) in a head-to-head manner. Background: EES have been shown to be superior to paclitaxel-eluting stents in inhibiting late loss (LL) and clinical outcome. Whether EES may provide similar angiographic and clinical outcomes compared with SES is undetermined. Methods: This was a prospective, randomized, open-label, multicenter trial to demonstrate the noninferiority of EES compared with SES in preventing LL at 9 months. A total of 1,443 patients undergoing percutaneous coronary intervention were randomized 3:1 to receive EES or SES. Routine follow-up angiography was recommended at 9 months. The primary endpoint was in-segment LL at 9 months, and major secondary endpoints included in-stent LL at 9 months, target lesion failure, cardiac death, nonfatal myocardial infarction, target lesion revascularization, and stent thrombosis at 12 months. Data were managed by an independent management center, and clinical events were adjudicated by an independent adjudication committee. Results: Clinical follow-up was available in 1,428 patients and angiographic follow-up in 924 patients (1,215 lesions). The primary endpoint of the study (in-segment LL at 9 months) was 0.11 ± 0.38 mm and 0.06 ± 0.36 mm for EES and SES, respectively (p for noninferiority = 0.0382). The in-stent LL was also noninferior (EES 0.19 ± 0.35 mm; SES 0.15 ± 0.34 mm; p for noninferiority = 0.0121). The incidence of clinical endpoints was not statistically different between the 2 groups, including target lesion failure (3.75% vs. 3.05%; p = 0.53) and stent thrombosis (0.37% vs. 0.83%; p = 0.38). Conclusions: EES were noninferior to SES in inhibition of LL after stenting, which was corroborated by similar rates of clinical outcomes. (Efficacy of Xience/Promus Versus Cypher in Reducing Late Loss After Stenting [EXCELLENT]; NCT00698607)

Original languageEnglish
Pages (from-to)1844-1854
Number of pages11
JournalJournal of the American College of Cardiology
Issue number18
Publication statusPublished - 2011 Oct 25

Bibliographical note

Funding Information:
This study was supported by a grant from the Clinical Research Center for Ischemic Heart Disease , Seoul, Republic of Korea ( 0412-CR02-0704-0001 ), and a grant from the Innovative Research Institute for Cell Therapy , Seoul National University Hospital ( A062260 ), sponsored by the Ministry of Health, Welfare & Family, Republic of Korea. The authors also received unrestricted grants from Abbott Vascular Korea and Boston Scientific Korea . The funding source of the study had no role in study design, data collection, monitoring, analysis, interpretation, or writing of the manuscript. The authors have reported that they have no relationships relevant to the contents of this paper to disclose.

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Everolimus-eluting versus sirolimus-eluting stents in patients undergoing percutaneous coronary intervention: The excellent (efficacy of Xience/Promus versus cypher to reduce late loss after stenting) randomized trial'. Together they form a unique fingerprint.

Cite this